Precigen Achieves Significant Clinical Progress for UltraCAR-T and AdenoVerse Therapies - 50% (3 out of 6) objective response rate (ORR) in relapsed or refractory (r/r) acute myeloid leukemia (AML) patients treated with

Precigen Achieves Significant Clinical Progress

for UltraCAR-T and AdenoVerse Therapies

50% (3 out of 6) objective response rate (ORR) in relapsed or refractory (r/r) acute myeloid leukemia (AML) patients treated with PRGN-3006

at the two lowest dose levels (a single administration of 4 to 28 million UltraCAR-T cells) in the lymphodepletion cohort of the ongoing

40% ORR (2 out of 5) and 60% disease control rate (DCR) (3 out of 5) in recurrent or metastatic human papilloma virus (HPV)-associated

cancer patients treated in the PRGN-2009 combination arm of the ongoing Phase 1 trial -

Preliminary PRGN-2012 Phase 1 data show encouraging clinical activity, including ongoing reduction/elimination of the need for surgical

intervention at the most recent follow-up, up to 12 weeks after PRGN-2012 treatment -

PRGN-3005 and PRGN-3006 UltraCAR-T demonstrate favorable safety profiles with no dose-limiting toxicities or neurotoxicity, dose-dependent

in vivo expansion and durable persistence -

PRGN-2009 and PRGN-2012 AdenoVerse immunotherapies demonstrate favorable safety profiles with no dose-limiting toxicities, strong antigen-specific

immune response and lack of significant neutralizing antibody response upon repeat administrations -

PRGN-3006 clinical abstract (Abstract# 825) selected for oral presentation at the 63rd American Society of Hematology (ASH) Annual Meeting

Precigen to host 2021 R&D Day virtual event today at 11:00 AM ET -

GERMANTOWN, MD, November 4, 2021 -

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative

gene and cell therapies to improve the lives of patients, announced a topline summary of the presentations planned for today's

2021 R&D Day virtual event, which begins at 11:00 AM ET. Participants may register and access the live webcast through Precigen's

investor relations website in the Events & Presentations

event will showcase clinical progress for Precigen's UltraCAR-T platform, including PRGN-3005 UltraCAR-T, PRGN-3006 UltraCAR-T,

PRGN-3007 UltraCAR-T and the AdenoVerse Immunotherapy platform, including PRGN-2009 off-the-shelf (OTS) AdenoVerse immunotherapy and

PRGN-2012 OTS AdenoVerse Immunotherapy. Presentations will be made by Precigen executives and clinical trial investigators,

R&D Day highlights the most significant clinical data presented for the UltraCAR-T and AdenoVerse platforms to date," said

Helen Sabzevari, PhD, President and CEO of Precigen, "and we are highly encouraged by the initial results we are seeing across

assets in both platforms. With UltraCAR-T, initial data for PRGN-3005 and PRGN-3006 continue to demonstrate favorable safety

profiles, dose-dependent expansion, and durable persistence. The very encouraging clinical responses in relapsed or refractory AML

patients treated with PRGN-3006 at the two lowest

the lymphodepletion cohort, which are administered at significantly lower doses than competing approaches, highlight the potential of

the UltraCAR-T platform. Our AdenoVerse immunotherapy platform is equally impressive with initial data for PRGN-2009 and PRGN-2012 showing

antigen-specific immune responses, low neutralizing antibody responses, and favorable safety profiles highlighting the potential for repeat

administrations. Preliminary data for PRGN-2009 show encouraging objective responses and suggest an attractive opportunity for potential

combination of PRGN-2009 with checkpoint inhibitors in multiple HPV-associated cancers. Finally, preliminary data for PRGN-2012 show encouraging

clinical responses in RRP patients, including a reduction in surgical interventions following PRGN-2012 treatment. We are on track to

pursue potentially registrational trials for therapeutic candidates in both the UltraCAR-T and AdenoVerse platforms upon dose confirmation

PRGN-3006 UltraCAR-T

Non-lymphodepletion Cohort (Cohort 1)

Lymphodepletion Cohort (Cohort 2)

PRGN-3005 UltraCAR-T

Generation UltraCAR-T with Intrinsic PD-1 Inhibition

PRGN-2012 OTS AdenoVerse Immunotherapy

PRGN-2009 OTS AdenoVerse Immunotherapy

Precigen: Advancing Medicine with Precision

Precigen (Nasdaq: PGEN) is a dedicated discovery

and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target

the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.

Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an

innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept

and commercialization. For more information about Precigen, visit www.precigen.com or follow us

on Twitter @Precigen and LinkedIn.

UltraCAR-T is a multigenic autologous CAR-T platform

that utilizes Precigen's advanced non-viral Sleeping Beauty system to simultaneously express an antigen-specific CAR to specifically

target tumor cells, mbIL15 for enhanced in vivo expansion and persistence, and a kill switch to conditionally eliminate CAR-T cells

for a potentially improved safety profile. Precigen has advanced the UltraCAR-T platform to address the inhibitory tumor microenvironment

by incorporating a novel mechanism for intrinsic checkpoint blockade without the need for complex and expensive gene editing techniques.

UltraCAR-T investigational therapies are manufactured via Precigen's overnight manufacturing process using the proprietary UltraPorator

electroporation system at the medical center and administered to patients only one day following gene transfer. The overnight UltraCAR-T

manufacturing process does not use viral vectors and does not require ex vivo activation and expansion of T cells, potentially

addressing major limitations of current T cell therapies.

AdenoVerse Immunotherapy

Precigen's AdenoVerse immunotherapy platform utilizes

a library of proprietary adenovectors for the efficient gene delivery of therapeutic effectors, immunomodulators, and vaccine antigens

designed to modulate the immune system. Precigen's gorilla adenovectors, part of the AdenoVerse library, have potentially superior performance

characteristics as compared to current competition. AdenoVerse immunotherapies have been shown to generate high-level and durable antigen-specific

neutralizing antibodies and effector T cell immune responses as well as an ability to boost these antibody and T cell responses via repeat administration.

Superior performance characteristics and high yield manufacturing of AdenoVerse vectors combined with UltraVector technology

allows Precigen to engineer cutting-edge investigational gene therapies to treat complex diseases.

The UltraPorator system is an exclusive

device and proprietary software solution for the scale-up of rapid and cost-effective manufacturing of UltraCAR-T therapies

and potentially represents a major advancement over current electroporation devices by significantly reducing the processing time and

contamination risk. The UltraPorator device is a high-throughput, semi-closed electroporation system for modifying T cells using Precigen's

proprietary non-viral gene transfer technology. UltraPorator is being utilized for clinical manufacturing of Precigen's investigational

UltraCAR-T therapies in compliance with current good manufacturing practices.

Precigen, UltraCAR-T, AdenoVerse, UltraVector,

UltraPorator and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks

of their respective owners.

Cautionary Statement Regarding Forward-Looking

Some of the statements made in this press release

are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about

future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the

timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio

of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected

in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including

the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results

may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation

to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly

qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important

factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the

section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the

Securities and Exchange Commission.